The Food and Drug Administration Oct. 14 approved Inmazeb for treating Zaire ebolavirus infection in adult and pediatric patients. The drug is a mixture of three monoclonal antibodies (atoltivimab, maftivimab and odesivimab-ebgn) that, when combined, target glycoprotein on the Ebola virus’ surface to block its attachment and entry into the human body.

“Today’s approval highlights the importance of international collaboration in the fight against Ebola virus,” said John Farley, M.D., MPH, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research. “The urgent need for advanced therapies to combat this infectious disease is clear, and today’s action is a significant step forward in that effort.”

Related News Articles

Headline
The Democratic Republic of the Congo has reported 100 confirmed or probable Ebola cases and 43 deaths in Equateur Province since June 1, the World Health…
Headline
The Centers for Disease Control and Prevention yesterday joined the World Health Organization to declare the end of the Ebola Virus Disease outbreak in the…
Headline
The Food and Drug Administration yesterday approved the first FDA-approved vaccine to prevent Ebola in adults with Zaire ebolavirus, which killed more…
Headline
The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living…
Headline
The Department of Health and Human Services yesterday awarded $20.5 million to develop vaccine candidates for Marburg virus and Sudan ebolavirus, which…
Headline
The World Health Organization recently deployed a rapid response team and personal protective equipment to the United Republic of Tanzania following unofficial…